Otonomy (NASDAQ: OTIC) is one of 283 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Otonomy to related companies based on the strength of its risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.
This is a breakdown of recent recommendations and price targets for Otonomy and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Otonomy and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Otonomy Competitors||$286.20 million||$34.74 million||136.84|
Otonomy’s competitors have higher revenue and earnings than Otonomy. Otonomy is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Otonomy and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
66.1% of Otonomy shares are owned by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 12.7% of Otonomy shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Otonomy has a beta of 2.81, meaning that its stock price is 181% more volatile than the S&P 500. Comparatively, Otonomy’s competitors have a beta of 1.87, meaning that their average stock price is 87% more volatile than the S&P 500.
Otonomy competitors beat Otonomy on 8 of the 12 factors compared.
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.